Ocuphire Pharma: KOL Event on Oral APX3330 for Diabetic Retinopathy and Diabetic Macular Edema
About The Event
Join us for a KOL Webinar with Ocuphire Pharma, featuring Peter Kaiser, MD (Cleveland Clinic), Caroline Baumal, MD (Tufts Medical Center), and David Lally, MD (New England Retina Consultants). KOL presentations will lead a discussion on Ocuphire’s APX3330, a novel, first-in-class oral tablet currently in Phase 2b for diabetic retinopathy (DR) and diabetic macular edema (DME). The focus will be on the current treatment landscape and design of the Phase 2b trial, which is expected to read out by the end of 2022.
A live question & answer session will follow.